Home > Insider Trading > Filing (0000950170-24-076225)

Filing Details

Accession Number:: 0000950170-24-076225
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-06-21 16:05:43
Reporting Period:: 2024-06-18

Accepted Time:: 2024-06-21 16:05:43
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
818686	Teva Pharmaceutical Industries Ltd	TEVA	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1258394	Roberto Mignone	C/O Teva Pharmaceutical Industries Ltd. 124 Dvora Hanevi'A St., Tel Aviv L3 6944020		No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Disposition	2024-06-18	519,000	$17.03	981,000	No	4	S	Indirect	[see footnote]

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	[see footnote]

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Ordinary Shares	95,683	Direct

Footnotes

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.96 to $17.16, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
The 981,000 Ordinary Shares disclosed in Table I of this Form 4 are held of record by Swiftcurrent Master Fund, Ltd. (the "Fund"). Bridger Management, LLC is the investment adviser to the Fund and Mr. Mignone is the manager of Bridger Management, LLC. By reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone may be deemed to beneficially own the Ordinary Shares held of record by the Fund. Mr. Mignone disclaims beneficial ownership of the Ordinary Shares held of record by the Fund except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an admission that Mr. Mignone is the beneficial owner of the Ordinary Shares held of record by the Fund for purposes of Section 16, or for any other purpose.
The reported amount corrects an overstatement in the Form 4s filed on August 7, 2023 and June 17, 2024, which, after giving effect to the reported transactions, inadvertently duplicated the 1,500,000 indirectly held shares by also including such shares in the reporting person's direct holdings. The correct amount of shares directly owned after the reported transactions in such prior Form 4 filings should have been 74,575 shares and 95,683 shares, respectively.